Ndwm LLC Takes Position in Eli Lilly and Company (NYSE:LLY)

Ndwm LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 286 shares of the company’s stock, valued at approximately $222,000.

A number of other institutional investors and hedge funds have also bought and sold shares of LLY. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $26,000. Core Wealth Advisors Inc. boosted its position in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares during the last quarter. Tidemark LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $29,000. Redmont Wealth Advisors LLC bought a new position in shares of Eli Lilly and Company in the 1st quarter worth about $40,000. Finally, Frank Rimerman Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $37,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.9 %

Shares of Eli Lilly and Company stock opened at $898.10 on Friday. The stock has a market capitalization of $853.56 billion, a P/E ratio of 132.27, a P/E/G ratio of 1.96 and a beta of 0.41. Eli Lilly and Company has a 52-week low of $434.34 and a 52-week high of $918.50. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The stock’s 50-day simple moving average is $828.07 and its 200 day simple moving average is $747.74.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same period in the previous year, the business earned $1.62 EPS. Eli Lilly and Company’s revenue was up 26.0% compared to the same quarter last year. As a group, research analysts anticipate that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 8,848 shares of the stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total value of $8,098,662.88. Following the transaction, the insider now owns 97,299,772 shares of the company’s stock, valued at approximately $89,059,454,309.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, major shareholder Lilly Endowment Inc sold 8,848 shares of the stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total value of $8,098,662.88. Following the transaction, the insider now owns 97,299,772 shares of the company’s stock, valued at $89,059,454,309.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares in the company, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Insiders sold a total of 858,742 shares of company stock worth $735,573,781 over the last ninety days. 0.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on LLY shares. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Argus increased their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research note on Tuesday, May 14th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Citigroup boosted their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Finally, JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $812.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.